Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PALATIN TECHNOLOGIES, INC.

(PTN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

HC Wainwright Adjusts Palatin Technologies' Price Target to $5 From $2, Keeps Buy Rating

11/24/2021 | 07:19am EST


ę MT Newswires 2021
All news about PALATIN TECHNOLOGIES, INC.
01/24Palatin Announces Presentation at the 2022 Crohn's and Colitis Congress
AQ
2021Palatin Technologies Starts Late-Stage Dry Eye Disease Trial
MT
2021Palatin Technologies, Inc. Announces Initiation of Pivotal Phase 3 Pl9643 Melody-1 Clin..
CI
2021Palatin Gets US Patent to Use Melanocortin Peptides to Treat Immune System Dysregulatio..
MT
2021Top Premarket Gainers
MT
2021HC Wainwright Adjusts Palatin Technologies' Price Target to $5 From $2, Keeps Buy Ratin..
MT
2021PALATIN TECHNOLOGIES : Reports First Quarter Fiscal Year 2022 Resultsand Provides Corporat..
PU
2021PALATIN TECHNOLOGIES INC : Results of Operations and Financial Condition (form 8-K)
AQ
2021Earnings Flash (PTN) PALATIN TECHNOLOGIES Reports Q1 Revenue $159,482, vs. Street Est o..
MT
2021PALATIN TECHNOLOGIES INC Management's Discussion and Analysis of Financial Condition a..
AQ
More news
Analyst Recommendations on PALATIN TECHNOLOGIES, INC.
More recommendations
Financials (USD)
Sales 2022 2,31 M - -
Net income 2022 -29,4 M - -
Net Debt 2022 - - -
P/E ratio 2022 -3,30x
Yield 2022 -
Capitalization 91,5 M 91,5 M -
Capi. / Sales 2022 39,6x
Capi. / Sales 2023 12,8x
Nbr of Employees 26
Free-Float -
Chart PALATIN TECHNOLOGIES, INC.
Duration : Period :
Palatin Technologies, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PALATIN TECHNOLOGIES, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 0,40 $
Average target price 3,33 $
Spread / Average Target 743%
EPS Revisions
Managers and Directors
Carl Spana Director
Stephen T. Wills COO, CFO, Secretary, Treasurer & Executive VP
John K. A. Prendergast Director
Michael B. Raizman Chief Medical Officer
John Dodd Senior Vice President-Preclinical Development
Sector and Competitors
1st jan.Capi. (M$)
PALATIN TECHNOLOGIES, INC.-22.69%91
GILEAD SCIENCES, INC.-5.16%86 377
REGENERON PHARMACEUTICALS-1.05%65 339
VERTEX PHARMACEUTICALS10.66%61 849
WUXI APPTEC CO., LTD.-11.62%47 600
BIONTECH SE-37.08%39 180